SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : P&S and STO Death Blow's
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jeff who started this subject5/23/2002 5:34:00 PM
From: exp   of 30712
 
FDA Panel Endorses Biogen's Skin-Condition Drug Amevive

Thursday May 23, 5:03 pm Eastern Time
FDA Panel Endorses Biogen's Skin-Condition Drug Amevive

Dow Jones Newswires

WASHINGTON -- Biogen Inc. (NasdaqNM: BGEN - News) (BGEN) convinced a federal advisory panel Thursday that its experimental psoriasis drug Amevive should be approved for the serious skin condition.

This victory moves Amevive closer to the market, as the Food and Drug Administration usually approves drugs recommended by its panel of outside advisers. FDA approval is even more likely since the panel's vote wasn't close with eight voting in favor of approval and just two saying the drug shouldn't be allowed on the market....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News